Zhang Xue, Zhang Wei, Zhang Huan, Liao Xuelian
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Institute of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Immunol. 2025 Feb 6;16:1546474. doi: 10.3389/fimmu.2025.1546474. eCollection 2025.
Sepsis, a heterogeneous illness produced by a dysregulated host response to infection, remains a severe mortality risk. Recent discoveries in sepsis research have stressed phenotyping as a feasible strategy for tackling heterogeneity and enhancing therapy precision. Sepsis phenotyping has moved from traditional stratifications based on severity and prognosis to dynamic, phenotype-driven therapeutic options. This review covers recent progress in connecting sepsis subgroups to personalized treatments, with a focus on phenotype-based therapeutic predictions and decision-support systems. Despite ongoing challenges, such as standardizing phenotyping frameworks and incorporating findings into clinical practice, this topic has enormous promise. By investigating phenotypic variation in therapy responses, we hope to uncover new biomarkers and phenotype-driven therapeutic solutions, laying the groundwork for more effective therapies and, ultimately improving patient outcomes.
脓毒症是宿主对感染的反应失调所导致的一种异质性疾病，仍然是严重的死亡风险。脓毒症研究的最新发现强调表型分型是应对异质性和提高治疗精准度的可行策略。脓毒症表型分型已从基于严重程度和预后的传统分层转向动态的、由表型驱动的治疗选择。本综述涵盖了将脓毒症亚组与个性化治疗相联系的最新进展，重点关注基于表型的治疗预测和决策支持系统。尽管存在持续的挑战，如使表型分型框架标准化以及将研究结果纳入临床实践，但该主题具有巨大的前景。通过研究治疗反应中的表型变异，我们希望发现新的生物标志物和由表型驱动的治疗方案，为更有效的治疗奠定基础，并最终改善患者预后。
